Navigation Links
Stronger Backing for Drug-Coated Stents

New research proves drug-coated stents effectively combat death, heart attack and repeat procedures in the real world.//

A new study from researchers in the Netherlands indicates that patients in clinical trials of drug-coated stents represented a very select group of the total population. This new study takes a closer look at the effects of drug-coated stents on real-world patients, patients the researchers say tend to be older and sicker than those selected for clinical trials.

The study included more than 500 patients with previously untreated blocked arteries who were treated with drug-eluting stents. An additional 450 patients with comparable blockages were treated with bare metal stents. Sixty-eight percent of the patients in this trial did not meet the selection criteria of previous clinical trials.

Results of the one-year study show 9.7 percent of patients who received drug-eluting stents had a major adverse cardiac event, compared with 14.8 percent of patients treated with bare metal stents. Only 3.7 percent of patients with drug-eluting stents experienced renarrowing of the treated vessel, a common complication that leads to corrective procedures. However, 10.9 percent of patients with bare metal stents required repeat procedures to correct renarrowing of the artery.

Lead investigator Patrick W. Serruys, M.D., Ph.D., from Erasmus Medical Center in the Netherlands, says, “The treatment effects -- particularly the reduction of re-interventions -- were similar across very different subgroups of patients.” He says drug-eluting stents are the next major step in interventional cardiology.

In an accompanying editorial, David P. Fason, M.D., from the University of Chicago, says the research results “go a long way in re-assuring the practitioner that drug-eluting stents are in fact safe and effective in a wide variety of patients undergoing ‘real world’ angioplasty.” He concludes that the next step shoul d be a mandatory registry established by the Food and Drug Administration to report problems.


'"/>




Related medicine news :

1. Health Care Ties To Get Stronger Between India And Britain
2. Women Portray Stronger Immune Response As Compared to Men, Study Suggests
3. Stronger Doses Fewer Administration for Breast Cancer
4. Stronger Quadricep Controls Knee Osteoarthritis
5. Old Indian Advice Has A Scientific Backing Now!
6. Fury over Backing of Health Shake-up
7. Failure of Drug-Coated Stent
8. Drug-Coated Stent
9. Drug-Coated Stents – Proven to be More Effectiv
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Drug-Coated Stents – Proven to be More Effectiv
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... human performance, is proud to announce that it has received 510(k) clearance from ... the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... Clara, CA (PRWEB) , ... April 25, 2017 ... ... announces the addition of predictive analytics to its patient care management module. Using ... compliance even before a patient has been initiated on continuous positive airway pressure ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: